These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 26278330

  • 1. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
    Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y.
    Mol Ther; 2015 Nov; 23(11):1772-1782. PubMed ID: 26278330
    [Abstract] [Full Text] [Related]

  • 2. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [Abstract] [Full Text] [Related]

  • 3. Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis.
    Liu CH, Chan KM, Chiang T, Liu JY, Chern GG, Hsu FF, Wu YH, Liu YC, Chen Y.
    Mol Pharm; 2016 Jul 05; 13(7):2253-62. PubMed ID: 27224003
    [Abstract] [Full Text] [Related]

  • 4. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 5. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG.
    Hepatology; 2015 May 31; 61(5):1591-602. PubMed ID: 25529917
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J, Li R, Gao D, Chen F, Xie H.
    Int J Nanomedicine; 2020 May 31; 15():5701-5718. PubMed ID: 32848392
    [Abstract] [Full Text] [Related]

  • 8. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
    Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG.
    Sci Rep; 2017 Mar 09; 7():44123. PubMed ID: 28276530
    [Abstract] [Full Text] [Related]

  • 9. Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
    Lu L, Lu M, Pei Y, Chen J, Qin L, Zhu W, Jia H.
    Acta Biochim Biophys Sin (Shanghai); 2015 Dec 09; 47(12):988-96. PubMed ID: 26607439
    [Abstract] [Full Text] [Related]

  • 10. Antiangiogenic therapies for advanced hepatocellular carcinoma.
    Sampat KR, O'Neil B.
    Oncologist; 2013 Dec 09; 18(4):430-8. PubMed ID: 23576483
    [Abstract] [Full Text] [Related]

  • 11. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
    Shen J, Sun H, Meng Q, Yin Q, Zhang Z, Yu H, Li Y.
    Mol Pharm; 2014 Oct 06; 11(10):3342-51. PubMed ID: 24495194
    [Abstract] [Full Text] [Related]

  • 12. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
    Pazo-Cid RA, Lanzuela M, Esquerdo G, Pérez-Gracia JL, Antón A, Amigo G, Trufero JM, García-Otín AL, Martín-Duque P.
    Clin Transl Oncol; 2012 Aug 06; 14(8):564-74. PubMed ID: 22855137
    [Abstract] [Full Text] [Related]

  • 13. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
    Han L, Tang C, Yin C.
    Biomaterials; 2014 May 06; 35(15):4589-600. PubMed ID: 24613049
    [Abstract] [Full Text] [Related]

  • 14. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 15. Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
    Zheng G, Zhao R, Xu A, Shen Z, Chen X, Shao J.
    Eur J Pharm Sci; 2018 Jan 01; 111():492-502. PubMed ID: 29107835
    [Abstract] [Full Text] [Related]

  • 16. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
    Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y.
    Theranostics; 2018 Jan 01; 8(4):894-905. PubMed ID: 29463989
    [Abstract] [Full Text] [Related]

  • 17. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H, Zhang C, Chi H, Meng Z.
    Int J Oncol; 2018 Jun 01; 52(6):2051-2060. PubMed ID: 29620259
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 01; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 19. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
    Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS.
    J Natl Cancer Inst; 2016 Aug 01; 108(8):. PubMed ID: 27059374
    [Abstract] [Full Text] [Related]

  • 20. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B, Sharma A, Woo S.
    PLoS One; 2015 Aug 01; 10(9):e0139237. PubMed ID: 26414070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.